Headache . 2025 Dec 19. doi: 10.1111/head.70000. Online ahead of print. Benoit Gerard , Hubert Praudel , Michel Lanteri-Minet , Elise Van Obberghen , Fanny Rocher-Moreau , Johanna Rousset , Ulysse Jacquier , Sylvie Leroy , Margot Delin Abstract Background: Eptinezumab is an anti-calcitonin gene-related peptide monoclonal antibody used for
Moderate to Severe Acute Migraine Attacks: An Opinion Paper on the Use of Triptans and Triptan-NSAIDs Combinations in Individualized Treatment Plans
Neurology and therapy 2025 Dec 18. doi: 10.1007/s40120-025-00874-z. Online ahead of print. Peter J Goadsby , Alexandra J Sinclair , Shazia K Afridi , Christian Lucas , Jerôme Mawet , Michel Lanteri-Minet , Xavier Moisset , Hans Christoph Diener , Charly Gaul , Tim Patrick Jürgens , Marja-Liisa Sumelahti , Margarita Sanchez
Trends in the real-world management of cluster headache patients treated by subcutaneous sumatriptan and/or oxygen in France – An analysis of the French National Social Security System Open Data over eleven years (2014-2024)
Revue Neurologique (Paris) . 2025 Dec 16:S0035-3787(25)00653-8. doi: 10.1016/j.neurol.2025.11.004. Online ahead of print. E K Van Obberghen , R Fabre, L Bailly , M Lanteri-Minet Abstract The burden of cluster headache (CH) requires better knowledge of management to improve it. Objectives: To describe changes in
Cluster headache suicidality: a systematic review with a meta-analysis
The Journal of Headache and Pain . 2025 Dec 4;26(1):281. doi: 10.1186/s10194-025-02140-x. E K Van Obberghen , R Fabre , M Lanteri-Minet Abstract Background: Suicide is considered as common in patients with cluster headache (CH) and is defined as ‘suicidal headache’. However, the exact
Migraine-related disability according to headache frequency subclassifications: A systematic review and meta-analysis
Cephalalgia 2025 Oct;45(10):3331024251385965. doi: 10.1177/03331024251385965. Epub 2025 Oct 17. Manjit Singh Matharu , Stephen Silberstein , Hsiangkuo Yuan , Deborah Edgar 3 Roos Colman , Todd J Schwedt , Michel Lanteri-Minet , Mark Obermann Abstract BackgroundThis systematic review and meta-analysis synthesized migraine-related disability outcomes according to headache frequency subclassifications,
Hallmarks of primary headache: part 3 – cluster headache
The Journal of Headache and Pain 2025 Oct 2;26(1):196. doi: 10.1186/s10194-025-02145-6. Gianluca Coppola , Marco Antônio Arruda , Messoud Ashina , Mads Barloese , Andrea Carmine Belin , Sara Bottiroli , Debashish Chowdhury , Roberto De Icco , Cherubino Di Lorenzo , Giulia Di Stefano , Jacob C A Edvinsson
Real-World Evaluation of Botulinum Toxin A in Focal Peripheral Neuropathic Pain: Longitudinal Outcomes
European Journal of Neurology 2025 Sep;32(9):e70362. doi: 10.1111/ene.70362. Eva Sole-Cruz, Elise Van Obberghen-Blanc, Chloé Hirtz, Imene Bennour, Michel Lanteri-Minet, Anne Donnet Abstract Background: Neuropathic pain (NP) is frequently resistant to conventional treatments. Botulinum toxin type A (BT-A) is a recommended option for focal peripheral NP, but
Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo-Controlled Study
European Journal of Neurology 2025 Aug;32(8):e70328. doi: 10.1111/ene.70328. Stewart J Tepper, David W Dodick, Michel Lanteri-Minet , David Dolezil, Raquel Gil-Gouveia, Christian Lucas, Karolina Piasecka-Stryczynska, Gyöngyi Szabó, Daniel D Mikol, Mahan Chehrenama, Denise E Chou, Zilu Liu, Gabriel Paiva da Silva Lima Abstract Background: Erenumab-induced medication overuse headache (MOH) remission in participants with
Paracetamol and Caffeine Combination in Pain Management: A Narrative Review
Pain Research & Management 2025 Jul 22:2025:9166828. doi: 10.1155/prm/9166828. eCollection 2025. Michel Lanteri-Minet , Rassa Pegahi Abstract Background: Paracetamol is one of the most commonly used analgesic and antipyretic drug, available as a single or a combined formulation. Caffeine is an adjuvant analgesic to
Prevalence, characteristics and management of migraine patients with triptan failure in primary care: the EMR France-Mig study
The Journal of Headache and Pain 2025 Jul 2;26(1):153. doi: 10.1186/s10194-025-02086-0. M Lanteri-Minet , C Casarotto, O Bretin, C Collin, M Gugenheim, V Raclot, A Cases, P A Squara, W Aissani, A Saighi, H Lefebvre Abstract Background: The most used treatments for migraine attacks are triptans, yet a considerable proportion of